Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (407 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: depressivedsm ivpurpose ofriskwomen
  Phrases that lowered it: asthmasubject whoinclusion exclusionscreeningjudged
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 72 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Sponsor's past trials: 170 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 70 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 92.9% (raises risk) · Drug's FDA history
• Maximum age: 65 (raises risk) · Who can join
• Keywords listed: 8 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression NCT04670081 · started 2021 · scored riskier than 63% of active trials completed
• A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD NCT06309277 · started 2024 · scored riskier than 24% of active trials completed
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression NCT03559192 · started 2018 · scored riskier than 65% of active trials completed
• A Study in Relapse Prevention of Treatment-Resistant Depression NCT00958568 · started 2009 · scored riskier than 36% of active trials completed
• A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy NCT05455684 · started 2022 · scored riskier than 69% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.